Financials
Financial year 2026
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 0
Profit
Caution€ -238,871
▲ 84% vs 2025
Debts
High€ 3.7 million
▲ 4% vs 2025
ViroVet from Leuven, company number BE0634891328, closed financial year 2026 with a result of € -238,871 after tax. For that financial year ViroVet recorded a gross margin of € 0 and equity of € -3.6 million. Compared with financial year 2025, the result moved from € -1.5 million to € -238,871. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
What happened at ViroVet?
What happened at ViroVet in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 238,871. Source: NBB ↗
- Patrik Haesen stepped down as director. NBB
- Biotech Fonds Vlaanderen NV stepped down as director. NBB
- VIVES Partners SRL stepped down as director. NBB
- Ilse Sienaert stepped down as director. NBB
- Capricorn Partners NV stepped down as director. NBB
- Esbee BV stepped down as director. NBB
- VIVES Partners SRL became a director. NBB
In short
From € 2.6 million loss in 2022 to € 238,871 loss in 2026.
A new publication or filing at ViroVet? We notify you, reason included.
Follow ViroVetNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Capricorn SCF NV (19.5%), Agri Investment Fund BV (19.5%), Biotech Fonds Vlaanderen NV (16.1%), AVF FPCI (12.5%), VIVES II - Louvain Technology Fund NV (9.8%) and Gemma Frisius - Fonds K.U. Leuven NV (8.1%).
Directors
According to the 2026 annual accounts
Patrik Haesen
Director
since 2021 · until 2026
Director · represented by Thomas Beke
Also active at: ETHERNA IMMUNOTHERAPIES, Flamingo Therapeutics
since 2020 · until 2026
Director · represented by Yannick Vancoppenolle
Also active at: NOVADIP BIOSCIENCES, TESSARES, AXINESIS +9 more
since 2024 · until 2026
since 2020 · until 2026
Director · represented by Ludwig Goris
Also active at: TS FLANDERS, Mulan Invest, CAPRICORN ICT ARKIV +28 more
since 2020 · until 2026
Managing director · represented by Erwin Blomsma
since 2020 · until 2026
Shareholders
19.5%
19.5%
AVF FPCI
12.5%
Elanco US Inc.
3.7%
Erwin Blomsma
1%
0.7%
Nesya Goris
0.4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Ambachtenlaan 1
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
WIX_COM, IL
Domain
Domain
virovet.com
Registered
2014-10-24
Registrar
Register.com - Network Solutions, LLC
Expires
2026-10-24
Website info
Features
Security
Network
Details
- Company number
- 0634.891.328
- VAT number
- BE 0634.891.328
- Registered office
- Ambachtenlaan 1, 3001 Leuven
- Names & denominations
- ViroVet
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 August 2015
- Peppol
- Active · Active since 15 Oct 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied